BR112012032537B8 - Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo - Google Patents

Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo

Info

Publication number
BR112012032537B8
BR112012032537B8 BR112012032537A BR112012032537A BR112012032537B8 BR 112012032537 B8 BR112012032537 B8 BR 112012032537B8 BR 112012032537 A BR112012032537 A BR 112012032537A BR 112012032537 A BR112012032537 A BR 112012032537A BR 112012032537 B8 BR112012032537 B8 BR 112012032537B8
Authority
BR
Brazil
Prior art keywords
lung cancer
subject
small cell
cell lung
methods
Prior art date
Application number
BR112012032537A
Other languages
English (en)
Other versions
BR112012032537B1 (pt
BR112012032537A2 (pt
Inventor
Riel-Mehan Michael
Wilcox Sheri
Ayers Deborah
Janjic Nebojsa
Gold Larry
Jarvis Thale
Original Assignee
Somalogic Inc
Somalogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc, Somalogic Operating Co Inc filed Critical Somalogic Inc
Publication of BR112012032537A2 publication Critical patent/BR112012032537A2/pt
Publication of BR112012032537B1 publication Critical patent/BR112012032537B1/pt
Publication of BR112012032537B8 publication Critical patent/BR112012032537B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Data Mining & Analysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioethics (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)

Abstract

MÉTODO IN VITRO PARA DIAGNÓSTICAR QUE UM INDIVÍDUO TEM OU NÃO TEM CÂNCER DE PULMÃO E PARA FORNECER INFORMAÇÃO SOBRE CÂNCER DE PULMÃO EM UM INDIVÍDUO. O presente pedido de patente inclui os marcadores biológicos, métodos, aparelhos, reagentes, sistemas e conjuntos para a detecção e diagnóstico de câncer de pulmão. Em um aspecto, o pedido proporciona marcadores biológicos que podem ser utilizados isoladamente ou em várias combinações para diagnosticar o câncer de pulmão ou permitir o diagnóstico diferencial de nódulos pulmonares como benigno ou maligno. Em outro aspecto, são proporcionados métodos para diagnosticar câncer de pulmão de um indivíduo, em que os métodos de detecção incluem, em uma amostra biológica de um indivíduo, pelo menos, um valor de marcador biológico correspondente a pelo menos um marcador biológico selecionado a partir do grupo de marcadores biológicos fornecidos na Tabela 18, Tabela 20, ou Tabela 21, em que o indivíduo é classificado como tendo câncer de pulmão, ou a probabilidade de o indivíduo ter câncer de pul mão é determinado, com base no valor de, pelo menos, um marcador biológico.
BR112012032537A 2010-07-09 2011-07-11 Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo BR112012032537B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36312210P 2010-07-09 2010-07-09
US61363122 2010-07-09
US201161444947P 2011-02-21 2011-02-21
US61444947 2011-02-21
PCT/US2011/043595 WO2012006632A2 (en) 2010-07-09 2011-07-11 Lung cancer biomarkers and uses thereof

Publications (3)

Publication Number Publication Date
BR112012032537A2 BR112012032537A2 (pt) 2017-05-23
BR112012032537B1 BR112012032537B1 (pt) 2021-03-02
BR112012032537B8 true BR112012032537B8 (pt) 2022-10-18

Family

ID=45441874

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012032537A BR112012032537B8 (pt) 2010-07-09 2011-07-11 Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo

Country Status (12)

Country Link
US (3) US20130116150A1 (pt)
EP (1) EP2591357A4 (pt)
JP (1) JP5905003B2 (pt)
KR (1) KR101870123B1 (pt)
CN (2) CN104777313B (pt)
AU (1) AU2011274422B2 (pt)
BR (1) BR112012032537B8 (pt)
CA (1) CA2801110C (pt)
IL (1) IL223295A (pt)
MX (2) MX2012014268A (pt)
SG (2) SG186953A1 (pt)
WO (1) WO2012006632A2 (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651185C (en) 2006-05-09 2022-08-30 The University Of British Columbia Dissolved protein arthritis markers
AU2008329529B2 (en) 2007-11-27 2015-02-19 The University Of British Columbia 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
US8285719B1 (en) 2008-08-08 2012-10-09 The Research Foundation Of State University Of New York System and method for probabilistic relational clustering
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
EP2406633B1 (en) 2009-03-11 2019-01-16 Augurex Life Sciences Corp. Compositions and methods for characterizing arthritic conditions
BR112013003391B8 (pt) 2010-08-13 2022-10-25 Somalogic Inc Método para diagnosticar câncer pancreático em um indivíduo
US20140235487A1 (en) * 2010-11-12 2014-08-21 William Marsh Rice University Oral cancer risk scoring
BR112014009536A2 (pt) 2011-10-21 2017-04-18 Augurex Life Sciences Corp antígenos derivados de 14-3-3 xitrulinada e usos dos mesmos no diagnóstico de artrite reumatoide
US20130282390A1 (en) * 2012-04-20 2013-10-24 International Business Machines Corporation Combining knowledge and data driven insights for identifying risk factors in healthcare
WO2013163568A2 (en) * 2012-04-26 2013-10-31 Allegro Diagnostics Corp. Methods for evaluating lung cancer status
JP6022285B2 (ja) * 2012-09-28 2016-11-09 シスメックス株式会社 標本収納装置、標本収納方法、及び標本検査システム
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
CA2928520C (en) 2012-10-23 2023-03-14 Caris Life Sciences Switzerland Holdings, S.A.R.L. Aptamers and uses thereof
US9103837B2 (en) 2012-11-07 2015-08-11 Somalogic, Inc. Chronic obstructive pulmonary disease (COPD) biomarkers and uses thereof
CA2895847C (en) 2012-12-19 2019-01-08 Caris Science, Inc. Compositions and methods for aptamer screening
WO2014186036A1 (en) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Methods for evaluating copd status
WO2014150198A2 (en) 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
WO2014153327A1 (en) 2013-03-18 2014-09-25 Barbeau James M Methods to determine carcinogenesis, identify markers for early cancer diagnosis and identify targets of therapy
US10501803B2 (en) * 2013-05-21 2019-12-10 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
KR101552014B1 (ko) 2013-10-11 2015-09-09 인제대학교 산학협력단 폐암 진단을 위한 nir의 신규한 용도
WO2015066564A1 (en) * 2013-10-31 2015-05-07 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
CN105814571B (zh) 2013-11-07 2020-01-07 曼迪奥研究有限公司 肺癌评估系统及计算机可读介质
PL3084664T3 (pl) * 2013-12-16 2020-10-05 Philip Morris Products S.A. Układy i sposoby do przewidywania statusu palenia u osobnika
RU2538625C1 (ru) * 2014-01-20 2015-01-10 Денис Николаевич Бахмутов Способ диагностики рака
WO2015164617A1 (en) 2014-04-24 2015-10-29 Somalogic, Inc. Tuberculosis biomarkers in urine and uses thereof
WO2015164616A1 (en) 2014-04-24 2015-10-29 Somalogic, Inc. Biomarkers for detection of tuberculosis
WO2015164772A1 (en) * 2014-04-25 2015-10-29 Rush University Medical Center Circulating insulin-like growth factor (igf)-associated proteins for the detection of lung cancer
AU2015289758B2 (en) * 2014-07-14 2021-09-09 Veracyte, Inc. Methods for evaluating lung cancer status
JP2017530356A (ja) 2014-09-26 2017-10-12 ソマロジック, インコーポレイテッドSomaLogic, Inc. 心血管系のリスクイベントの予測及びその使用
CN107206043A (zh) 2014-11-05 2017-09-26 维拉赛特股份有限公司 使用机器学习和高维转录数据在经支气管活检上诊断特发性肺纤维化的系统和方法
WO2016123058A1 (en) 2015-01-27 2016-08-04 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
US20180356419A1 (en) 2015-05-08 2018-12-13 Somalogic, Inc. Biomarkers for detection of tuberculosis risk
CN115097133A (zh) * 2015-09-09 2022-09-23 私募蛋白质体操作有限公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
KR102087373B1 (ko) * 2015-09-11 2020-03-10 주식회사 압타머사이언스 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법
US10546650B2 (en) 2015-10-23 2020-01-28 Google Llc Neural network for processing aptamer data
EP3414575A1 (en) 2016-02-08 2018-12-19 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
JP6041331B1 (ja) 2016-02-26 2016-12-07 国立大学法人山口大学 情報処理装置と情報処理プログラム並びに情報処理方法
JP6889428B2 (ja) * 2016-02-26 2021-06-18 国立大学法人山口大学 情報処理装置と情報処理プログラム並びに情報処理方法
CN107435062B (zh) * 2016-05-25 2020-10-20 上海伯豪医学检验所有限公司 甄别肺部微小结节良恶性的外周血基因标志物及其用途
CA3026650A1 (en) * 2016-06-08 2017-12-14 Research Development Foundation Systems and methods for automated coronary plaque characterization and risk assessment using intravascular optical coherence tomography
BR112018076528A2 (pt) * 2016-06-21 2019-04-02 The Wistar Institute Of Anatomy And Biology composições e métodos para diagnosticar cânceres de pulmão usando perfis de expressão gênica
JP2020522690A (ja) * 2017-06-02 2020-07-30 ベラサイト インコーポレイテッド 肺疾病の特定又はモニタリング方法及びシステム
CN109470855B (zh) * 2017-09-08 2022-02-11 广州市丹蓝生物科技有限公司 肺癌早期诊断用蛋白芯片及试剂盒
KR102028967B1 (ko) 2017-12-28 2019-10-07 한국원자력의학원 Ｒｉｐ1을 포함하는 폐암 전이 진단용 바이오 마커 및 이의 이용
US20210140977A1 (en) 2018-04-16 2021-05-13 University Of Cape Town A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis
WO2019246289A1 (en) * 2018-06-22 2019-12-26 Somalogic, Inc. Improved proteomic multiplex assays
WO2020018005A1 (en) * 2018-07-17 2020-01-23 Limited Liability Company "Gero" Devices, methods, compositions and systems for the treatment of aging and age- related disorders
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
EP3874043A4 (en) * 2018-10-30 2022-10-26 SomaLogic Operating Co., Inc. PROCEDURE FOR SAMPLE QUALITY ASSESSMENT
CN109470859A (zh) * 2018-11-04 2019-03-15 华东医院 一种外泌体蛋白作为鉴别肺结节良恶性标志物及其应用
EP3671210A1 (en) * 2018-12-21 2020-06-24 Biosystems International KFT Lung cancer protein epitomic biomarkers
WO2020243574A1 (en) * 2019-05-31 2020-12-03 Delphinus Medical Technologies, Inc. Systems and methods for interactive lesion characterization
US20210027890A1 (en) * 2019-07-24 2021-01-28 ConnSante BioTech, Inc. Detecting, evaluating and predicting system for cancer risk
CN114641692A (zh) 2019-09-03 2022-06-17 私募蛋白质体操作有限公司 心血管风险事件预测及其用途
EP4088117A1 (en) 2020-01-10 2022-11-16 SomaLogic Operating Co., Inc. Methods of determining impaired glucose tolerance
JP2023513470A (ja) 2020-01-30 2023-03-31 プログノミック インコーポレイテッド 肺バイオマーカーおよびそれらの使用方法
MX2022009517A (es) 2020-02-10 2022-09-02 Somalogic Operating Co Inc Biomarcadores de esteatohepatitis no alcoholica (nash) y usos de los mismos.
KR102260915B1 (ko) 2020-02-19 2021-06-04 한국원자력의학원 폐암의 방사선 치료 예후 예측을 위한 생체 표지자
CN111876478A (zh) * 2020-04-28 2020-11-03 中国科学院微生物研究所 肺结节诊断标志物及应用
US20230304099A1 (en) * 2020-08-14 2023-09-28 The Medical College Of Wisconsin, Inc. Gene Expression Signature for Predicting Immunotherapy Response and Methods of Use
JP2023545017A (ja) * 2020-10-02 2023-10-26 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 肺がんの検出及び治療のための方法
CN113960235B (zh) * 2020-10-10 2023-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 生物标志物在制备肺癌检测试剂中的用途和方法
US20230393146A1 (en) 2020-10-20 2023-12-07 Somalogic Operating Co., Inc. Cardiovascular Event Risk Prediction
GB2607436A (en) * 2021-03-31 2022-12-07 Prognomiq Inc Multi-omic assessment
CA3231038A1 (en) 2021-09-13 2023-03-16 Bruce Wilcox Enhanced detection and quantitation of biomolecules
CA3242172A1 (en) 2022-01-21 2023-07-27 David ASTLING Methods for sample quality assessment
AU2023259062A1 (en) 2022-04-24 2024-09-12 Somalogic Operating Co., Inc. Methods for sample quality assessment
AU2023260452A1 (en) 2022-04-24 2024-09-12 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023211769A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023211773A1 (en) 2022-04-24 2023-11-02 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2023244582A1 (en) * 2022-06-13 2023-12-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Lung cancer-related biomarkers and methods of using the same
WO2024010854A1 (en) * 2022-07-07 2024-01-11 Diagnose Early, Inc. Rapid generation of breath-based health reports and systems for use in the same
WO2024015485A1 (en) 2022-07-14 2024-01-18 Somalogic Operating Co., Inc. Methods of assessing dementia risk
WO2024015486A1 (en) 2022-07-14 2024-01-18 Somalogic Operating Co., Inc. Methods for sample quality assessment
WO2024064322A2 (en) 2022-09-23 2024-03-28 Somalogic Operating Co., Inc. Methods of assessing tobacco use status
US20240200125A1 (en) * 2022-12-16 2024-06-20 Droplet Biosciences, Inc. Analysis of effluent

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US20040254101A1 (en) 1995-06-06 2004-12-16 Human Genome Sciences, Inc. Colon specific gene and protein and cancer
AU6688598A (en) 1997-03-07 1998-09-22 University Of Florida Method for diagnosing and staging prostate cancer
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
EP1215500B1 (en) 1999-09-10 2008-07-09 Takashi Muramatsu Early cancer tumor marker
JP2004500100A (ja) 2000-03-06 2004-01-08 スミスクライン・ビーチャム・コーポレイション 新規化合物
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6596503B1 (en) 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6631330B1 (en) 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
US6576423B2 (en) 2000-12-08 2003-06-10 The Board Of Regents Of The University Of Nebraska Specific mucin expression as a marker for pancreatic cancer
CA2444691A1 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
AU2002343443A1 (en) 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
AU2002361908A1 (en) * 2001-12-31 2003-07-24 Quark Biotech, Inc. Methods for identifying marker genes for cancer
EP2241636A1 (en) 2002-03-13 2010-10-20 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
ES2320443T3 (es) 2002-09-30 2009-05-22 Oncotherapy Science, Inc. Genes y polipeptidos relacionados con canceres pancreaticos humanos.
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
WO2004055519A2 (en) 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
US8014952B2 (en) 2002-12-18 2011-09-06 Queen Elizabeth Hospital Serum biomarkers in lung cancer
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2003900747A0 (en) 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
AU2004213871B9 (en) 2003-02-20 2009-09-03 Genomic Health, Inc. Use of intronic RNA to measure gene expression
US20060134120A1 (en) 2003-02-26 2006-06-22 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
WO2004099432A2 (en) 2003-05-02 2004-11-18 The Johns Hopkins University Identification of biomarkers for detecting pancreatic cancer
CN1455257A (zh) * 2003-05-23 2003-11-12 北京师范大学 一种利用表面修饰蛋白芯片进行肺癌诊断方法
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DK3170906T3 (en) 2003-06-24 2018-11-05 Genomic Health Inc PREDICTION OF THE LIKELI REVENUE OF CANCER
WO2005008213A2 (en) 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20050069963A1 (en) 2003-08-15 2005-03-31 Lokshin Anna E. Multifactorial assay for cancer detection
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
US20070148648A1 (en) 2003-11-04 2007-06-28 Martin Dugas Method for distinguishing who classified aml subtypes
CA2557438C (en) 2004-02-19 2017-01-17 Yale University Identification of cancer protein biomarkers using proteomic techniques
WO2005086891A2 (en) 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
WO2005113798A2 (en) 2004-04-15 2005-12-01 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
US20060204951A1 (en) 2004-04-26 2006-09-14 Judah Folkman Platelet biomarkers for the detection of disease
WO2006022643A1 (en) 2004-07-26 2006-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting pancreatic disease
JP2008508538A (ja) 2004-08-02 2008-03-21 チルドレンズ・メディカル・センター・コーポレイション 癌についての血小板生物マーカー
ATE483979T1 (de) 2004-08-10 2010-10-15 Oncotherapy Science Inc Gen anln in verbindung mit nicht-kleinzelligem lungenkrebs und seine wechselwirkungen mit rhoa
JP2006053113A (ja) * 2004-08-16 2006-02-23 Medical Proteoscope Co Ltd 肺腺癌リンパ節転移診断方法及び診断キット
US7930104B2 (en) 2004-11-05 2011-04-19 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
ATE550440T1 (de) 2004-11-05 2012-04-15 Genomic Health Inc Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
US8632983B2 (en) 2005-04-15 2014-01-21 Van Andel Research Institute Biomarkers for pancreatic cancer and diagnostic methods
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20090005268A1 (en) 2005-07-18 2009-01-01 Epigenomics Ag Compositions and Methods for Cancer Diagnostics Comprising Pan-Cancer Markers
US7521195B1 (en) 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
CN101283106A (zh) 2005-07-27 2008-10-08 肿瘤疗法科学股份有限公司 小细胞肺癌的诊断方法
WO2007015947A2 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
US7582441B1 (en) 2005-10-17 2009-09-01 Celera Corporation Methods and compositions for treating and diagnosing disease
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
BRPI0619712A2 (pt) * 2005-11-10 2011-10-11 Univ Kentucky dispositivo para a identificação de um paciente como um candidato para testes radiográficos para o cáncer do pulmão, composição para detectar radiograficamente um cáncer do pulmão de estágio adiantado, dispositivo para o ensaio do cáncer do pulmão, uso de um painel, e, dispositivo de diagnóstico para a detecção do cáncer do pulmão
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2007076439A2 (en) 2005-12-22 2007-07-05 Abbott Laboratories Methods and marker combinations for screening for predisposition to lung cancer
US7695913B2 (en) 2006-01-11 2010-04-13 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
BRPI0707249A2 (pt) 2006-01-27 2011-04-26 Tripath Imaging Inc métodos para identificar pacientes com maior probabilidade de terem cáncer de ovário e composições para os mesmo
WO2007092433A2 (en) 2006-02-06 2007-08-16 Tethys Bioscience, Inc. Osteoporosis associated markers and methods of use thereof
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
AU2007313488A1 (en) 2006-04-04 2008-04-24 Singulex, Inc. Methods and compositions for highly sensitive analysis of markers and detection of molecules
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
WO2008003024A2 (en) 2006-06-28 2008-01-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method and composition for diagnosing endometrial cancer
WO2008046911A2 (en) 2006-10-20 2008-04-24 Exiqon A/S Novel human micrornas associated with cancer
CA2669600A1 (en) 2006-11-13 2008-05-29 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of lung cancer
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
KR100846354B1 (ko) * 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
US20100105571A1 (en) 2007-03-27 2010-04-29 Carl Arne Krister Borrebaeck Protein Signature/Markers for the Detection of Adenocarcinoma
RU2376372C2 (ru) 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
JP5256284B2 (ja) 2007-05-18 2013-08-07 デューク ユニバーシティ 肺癌早期発見のための血清バイオマーカー
US20100183514A1 (en) 2007-05-29 2010-07-22 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
EP2069496A4 (en) * 2007-07-17 2010-01-27 Somalogic Inc SELEX AND PHOTOSELEX ENHANCED
EP2019318A1 (en) 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
GB0717637D0 (en) 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
US8541183B2 (en) * 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
WO2009036123A1 (en) * 2007-09-11 2009-03-19 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
US20100267041A1 (en) 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
AU2008302526A1 (en) * 2007-09-18 2009-03-26 Board Of Regents Of The University Of Texas System Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
WO2009067546A2 (en) 2007-11-19 2009-05-28 Celera Corpration Lung cancer markers and uses thereof
WO2009091581A2 (en) 2008-01-18 2009-07-23 Vatrix Medical, Inc. Diagnostic biomarkers for vascular aneurysm
GB0803192D0 (en) 2008-02-22 2008-04-02 Mubio Products Bv SCLC biomarker panel
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
CN104198709A (zh) 2008-09-09 2014-12-10 私募蛋白质体公司 肺癌生物标记及其用途
US20120143805A1 (en) 2008-09-09 2012-06-07 Somalogic, Inc. Cancer Biomarkers and Uses Thereof
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20120165217A1 (en) 2008-10-06 2012-06-28 Somalogic, Inc. Cancer Biomarkers and Uses Thereof
US20110294683A1 (en) 2008-10-30 2011-12-01 Centre de Recherche Public de la Sant'e Biomarkers
GB2507680B (en) 2008-11-17 2014-06-18 Veracyte Inc Methods and compositions of molecular profiling for disease diagnostics
WO2010059742A1 (en) 2008-11-18 2010-05-27 Collabrx, Inc. Individualized cancer treatment
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
US8450069B2 (en) 2009-06-08 2013-05-28 Singulex, Inc. Highly sensitive biomarker panels
EP2264183B1 (en) 2009-06-09 2016-12-07 Gendiag.exe, S.L. Risk markers for cardiovascular disease
WO2010148017A1 (en) 2009-06-15 2010-12-23 Cardiodx, Inc. Determination of coronary artery disease risk.
AU2010284199A1 (en) 2009-08-19 2012-04-05 The Cleveland Clinic Foundation Marker detection for characterizing the risk of cardiovascular disease or complications thereof
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
US9683996B2 (en) 2009-10-22 2017-06-20 The Regents Of The University Of California Assessment of solid tumor burden
WO2011059721A1 (en) 2009-10-29 2011-05-19 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
EP2507397A4 (en) 2009-12-01 2013-05-01 Compendia Bioscience Inc CLASSIFICATION OF CANCERS
AU2010328019A1 (en) 2009-12-09 2012-06-28 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
WO2011094483A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer
WO2011100472A1 (en) 2010-02-10 2011-08-18 The Regents Of The University Of California Salivary transcriptomic and proteomic biomarkers for breast cancer detection
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US20110256545A1 (en) * 2010-04-14 2011-10-20 Nancy Lan Guo mRNA expression-based prognostic gene signature for non-small cell lung cancer
BR112013003391B8 (pt) 2010-08-13 2022-10-25 Somalogic Inc Método para diagnosticar câncer pancreático em um indivíduo
US20120077695A1 (en) 2010-09-27 2012-03-29 Somalogic, Inc. Mesothelioma Biomarkers and Uses Thereof
JP2014514572A (ja) * 2011-04-29 2014-06-19 キャンサー・プリヴェンション・アンド・キュア，リミテッド 分類システムおよびそのキットを使用した肺疾患の同定および診断方法
CA3074279C (en) 2011-09-30 2021-10-19 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CN103890586B (zh) 2011-10-24 2016-06-29 私募蛋白质体公司 肺癌生物标记及其用途
US9103837B2 (en) 2012-11-07 2015-08-11 Somalogic, Inc. Chronic obstructive pulmonary disease (COPD) biomarkers and uses thereof
AU2014353102B2 (en) 2013-11-21 2019-05-16 Somalogic Operating Co., Inc. Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto

Also Published As

Publication number Publication date
CA2801110C (en) 2021-10-05
IL223295A (en) 2016-11-30
US20130116150A1 (en) 2013-05-09
BR112012032537B1 (pt) 2021-03-02
WO2012006632A3 (en) 2012-05-18
EP2591357A4 (en) 2014-01-01
EP2591357A2 (en) 2013-05-15
BR112012032537A2 (pt) 2017-05-23
CN102985819B (zh) 2015-04-15
JP5905003B2 (ja) 2016-04-20
CN104777313B (zh) 2017-09-26
SG10201508656VA (en) 2015-11-27
MX2012014268A (es) 2013-02-12
CA2801110A1 (en) 2012-01-12
AU2011274422B2 (en) 2016-02-11
KR20130129347A (ko) 2013-11-28
JP2013532295A (ja) 2013-08-15
IL223295A0 (en) 2013-02-03
CN102985819A (zh) 2013-03-20
US20180275143A1 (en) 2018-09-27
CN104777313A (zh) 2015-07-15
MX355020B (es) 2018-04-02
KR101870123B1 (ko) 2018-06-25
WO2012006632A2 (en) 2012-01-12
US11221340B2 (en) 2022-01-11
SG186953A1 (en) 2013-02-28
AU2011274422A1 (en) 2012-12-20
US20120101002A1 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
BR112012032537B8 (pt) Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
BR112014006432A2 (pt) biomarcadores do câncer de pulmão e seus usos
GB2478441A (en) Lung cancer biomarkers and uses thereof
BR112012009879A2 (pt) "métodos diagnósticos para determinar o prognóstico de câncer de pulmão de não pequenos células"
BR112013009008A2 (pt) métodos e kits para a detecção de células circulantes de tumor em pacientes pancreáticos com o uso de reagentes de detecção de captura e de coquetel poliespecíficos
CY1119526T1 (el) Εμπλουτισμος και ταυτοποιηση εμβρυϊκων κυτταρων σε μητρικο αιμα και προσδετες για τετοια χρηση
MX2018004067A (es) Extinguidor que contiene nanomaterial conjugado con polimero soluble en agua y su uso.
BR112014010718A2 (pt) métodos e sistemas para detecção de analito em amostra
NZ709167A (en) Compositions and methods for diagnosing thyroid tumors
BR112018013430A2 (pt) ?métodos para detectar pelo menos uma mutação em uma pluralidade de genes relacionados a câncer de tireoide, para selecionar um sujeito que tem nódulos na tireoide e para prognosticar risco de malignidade, e, kit?
BRPI0620212B8 (pt) método de discriminação e de contagem de pelo menos duas populações de elementos biológicos portadoras de características específicas, e, utilização do método
BR112014015603B1 (pt) métodos para sondagem de múltiplos alvos em uma amostra biológica e para análise da amostra biológica de multiplexação de alta produtividade.
WO2008128043A3 (en) Diagnostic and prognostic methods for renal cell carcinoma
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
BR112017004098A2 (pt) ?detecção precoce de câncer por fenotipagem com metilação do dna das células derivadas do escarro?.
BR112012031444A2 (pt) método, arranjo e uso do mesmo
Mouliere A hitchhiker’s guide to cell-free DNA biology
WO2015023503A3 (en) Compositions and methods for multimodal analysis of cmet nucleic acids
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
WO2011163627A3 (en) Organ specific diagnostic panels and methods for identification of organ specific panel proteins
Moldovan et al. Genome-wide cell-free DNA termini in patients with cancer
Lyu et al. Septin 9 methylation in nasopharyngeal swabs: a potential minimally invasive biomarker for the early detection of nasopharyngeal carcinoma
CN103031372A (zh) Znf545基因甲基化定量检测方法
ATE486964T1 (de) Molekulares verfahren zur diagnose von prostatakrebs

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2011, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: SOMALOGIC OPERATING CO., INC. (US)